Enveric Biosciences(ENVB) - 2025 Q2 - Quarterly Results

Filing Information This section details the administrative information for the Form 8-K filing, including registrant identity and report date Registrant Details Provides administrative details of the Form 8-K filing, including registrant's legal name, jurisdiction, and report date - Registrant: Enveric Biosciences, Inc.[1] - Date of Report: August 14, 2025[1] - Jurisdiction of Incorporation: Delaware[1] Securities Information Details the registrant's registered securities under Section 12(b) and its emerging growth company status Registered Securities | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :------------------ | :---------------- | :---------------------------------------- | | Common stock, par value $0.01 per share | ENVB | The Nasdaq Stock Market | - The registrant is not an emerging growth company[3] Item 2.02 Results of Operations and Financial Condition Reports the issuance of a press release on August 14, 2025, detailing Q2 2025 financial results and corporate updates - A press release was issued on August 14, 2025, announcing Q2 2025 financial results and a corporate update[4] - Exhibit 99.1, the press release, is furnished and not deemed 'filed' under Section 18 of the Exchange Act[5] Item 9.01 Financial Statements and Exhibits Lists exhibits accompanying the Form 8-K filing, including the press release and interactive data file Exhibits Filed | Exhibit Number | Description | | :------------- | :---------- | | 99.1 | Press Release, dated August 14, 2025 (furnished pursuant to Item 2.02) | | 104 | Cover Page Interactive Data File (formatted as Inline XBRL) | Signatures Confirms the official signing of the report by Enveric Biosciences, Inc.'s CEO, Joseph Tucker, Ph.D., on August 14, 2025 - The report was signed by Joseph Tucker, Ph.D., Chief Executive Officer of Enveric Biosciences, Inc.[9] - The signing date for the report was August 14, 2025[9]